Noetic Fund

A venture fund launched by Grey House Partners GP Inc. to invest in emerging and early-stage wellness, therapeutic and pharmaceutical companies around the globe. We have proudly taken the North Star pledge and believe in the importance of stewarding this sector in the right way.



“From the Greek noēsis/ noētikos meaning inner wisdom, direct knowing, or subjective understanding”

Noetic science refers to a multidisciplinary field that brings objective scientific tools and techniques together with subjective understanding to study the full range of human experience.

  • Our Mission

    Our mission is to nurture the scientific advancement of mental, emotional, psychological and physical health by investing in alternative therapies, modalities, and sciences that are committed to optimizing our human experience.

  • Our Commitment

    We are committed to the development of pure, innovative and sustainable products and services that utilize technological innovation and the power of bioavailable plants that are often psychedelic in nature to help define a healthy future for our people and our planet.

  • Our Focus

    Psychedelic medicine and related sustainable solutions for mental health and physical well being.


Our Portfolio

Noetic Fund will focus on finding teams with the skills, expertise, management experience, and governance structures in place to build world class companies.

Delix Therapeutics

Delix Therapeutics

Delix Therapeutics is the developer of small-molecule drug compounds intended to help provide treatment against mental disorders. The company is offering enantiomer compounds for neural plasticity promoting, enabling healthcare service providers to cure patients suffering from depression, anxiety, and post-traumatic stress disorders.

Eve Health Systems

Eve Health Systems is a mental health services matching engine and practice management system, optimizing each piece of the experience for users seeking therapy.

GHP Noetic Science-Psychedelic Pharma Inc. TSXV: PSYF

GHP Noetic Science-Psychedelic Pharma Inc. is a Capital Pool Corporation (CPC) formed to assist a future qualifying transaction to access the capital markets to fund its growth and expansion.

Noetic Consciousness Inc.

Noetic Consciousness Inc. is a Capital Pool Corporation (CPC) formed to assist a future qualifying transaction to access the capital markets to fund its growth and expansion.

The Psynergia Alliance

Psynergia Alliance is a Life Sciences platform that backs, builds and incubates best-in-class companies in the mental wellness space with a focus on psychedelic therapeutics.

Meet the team

Our Team

Michael Franks

Managing Partner

6 years in venture capital, Silicon Valley, with focus on technology and software

20 years in mid-market M&A / Private Equity – c suite – private/publics – with top decile returns of 10x to 40x

BA in Economics from Queen’s University, Kingston

MBA from Trinity College, Dublin.

Naseem Saloojee

Managing Partner

6 years leading VC- and PE-backed growth businesses: SVP Sales at Top Hat (10X growth in 4 years) and CEO at Globalfaces Direct (100% growth in 2 years)

6 years as a consulting leader with McKinsey & Company, including a fellowship to McKinsey’s Social Sector Office

MBA from Harvard Business School.

Sa’ad Shah

Managing Partner

9 years at RBC Capital Markets in real estate banking, corporate credit, and derivative sales & trading

9 years at DGAM (acquired by The Carlyle Group) – Head of Marketing and Client Services, helped build AUM to $6.8B at peak

BA in Economics and Political Science from Columbia University.

Ashok Rao


20+ years in wholesale banking roles in New York, London, Toronto, Singapore and Bombay, covering syndicated & leveraged finance origination/structuring, global counterparty credit, and risk management at CIBC, BMO Capital Markets, TD Securities, and The Chase Manhattan Bank N.A.

MPA from Princeton University, BA in Economics (summa cum laude, Phi Beta Kappa) from Sewanee: The University of the South.

Evan Galasso


4 years working across startups, venture capital, and growth equity, including 2 years in investment analyst roles at XPV Water Partners (Toronto, water technology focus) and Khazanah Americas (San Francisco, healthcare technology focus)

BSc. in Science and Business (Biotechnology and Economics) from the University of Waterloo

Completed the CSC. AFM designation from Financial Modeling Institute.

Josh Hardman


5+ years research experience, from start-up market research to informing $3bn+ government spending envelopes

Founder of Psilocybin Alpha, leading resource for analysis of the emergent psychedelic sector

Consultant on numerous projects employing disruptive tech to solve societal issues

BSc Government (Harold Laski Scholar), the London School of Economics; with a year at UC Berkeley

Sri Teja Mullapudi, PhD


Experienced in investment opportunity analysis in life sciences from TIAP (previously MaRS Innovation)

7+ years of research experience with 8 publications in peer-reviewed journals

Ph.D. (summa cum laude) in Biology from the Max Planck Society, Germany

M.Tech + B.Tech in Biotechnology (Minor in Chemistry) from Indian Institute of Technology Madras, India

Soccer player with Toronto City FC.

Sara Nahon


1 year in Science Policy and Capacity Building Division, UNESCO

M.Res. in Psychiatry seeking to validate cognitive biomarkers measuring decline and pharmacological intervention in Parkinson’s disease, Somerville College, University of Oxford

B.Sc. in. Anatomy and Cell Biology, McGill University.

MatthewBaggott, Ph.D.

Matthew Baggott, PhD

Venture Partner

CEO of Tactogen

30-year career spanning data science, preclinical pharmacology, clinical research, neuroscience, genomics and drug development

Bachelor’s degree in Philosophy and Post-doctoral Fellow at the University of Chicago

Ph.D. in Neuroscience from the University of California, Berkeley.

Mark de Groot, PhD

Venture Partner

CEO of Pattern Pharma

30 years of experience founding and operating biotech ventures

DPhil in Physics from Christ Church College, University of Oxford

Bachelor’s in Mathematics from Trinity College, University of Toronto.

David Rabin, MD, PhD

Venture Partner

CIO of Apollo Neuroscience

Board-certified psychiatrist, neuroscientist, tech entrepreneur & inventor

Operates a clinical psychiatry practice and conducting research on the epigenetic regulation of trauma responses and recovery

Graduate degrees from Albany Medical College and psychiatric residency from Pittsburgh Medical Center.

Bryan Bullett


16+ years investment banking and capital markets at firms including Bank of America Merrill Lynch, Deutsche Bank and Friedman, Billings, Ramsey

Managing Director at Centerboard Securities, a boutique capital advisory firm based in New York City

Former US Head of Capital Markets for $14B funds management business

MBA from Columbia Business School

BA in Semiotics from Brown University.

Dr. Ede Frecska

Prof. Ede Frecska, PhD


Chairman of Psychiatry at the Faculty of Medicine of the University of Debrecen

Residency training in Psychiatry both in Hungary (1986), and in the United States (1992)

Qualified psychopharmacologist (1987) of international merit

17 years of clinical and research experience in the United States.

Jody Levy

Jody Levy


Jody Levy is an artist, designer, director, entrepreneur, executive and investor

Jody is the founder, creative director and Chief Executive Officer of a handful of companies dedicated to empowering people to be as healthy and happy as possible.

Dr. Luis Eduardo Luna

Luis Eduardo Luna, PhD


Guggenheim Fellow (1986), Fellow of the Linnaean Society of London (1989), and Doctor Honoris Causa, from St. Lawrence, Canton, New York (2002)

Ph.D. from the Department of Comparative Religion Stockholm University (1989)

Master from Oslo University (1980)

B.A. from Madrid University (1972).

Sam Tabar


17+ years legal and finance at firms including Bank of America Merrill Lynch and Skadden Arps

Managing Director at Centerboard Securities, a boutique capital advisory firm based in New York City

Former Global Head of Capital Strategy for a $20b funds management business

Former editor of the Columbia Business Law Journal

Graduated from Oxford University (BA) and Columbia Law School (LL.M.).

Warren Wright


9 years at Northwater Capital Management, as Managing Director – Head of Hedge Fund Investments

12 years at DGAM (acquired by The Carlyle Group) as Chief Investment Officer

Partner at The Carlyle Group and Chief Investment Officer of The Carlyle Liquid Markets Group.


Subscribe to keep in touch and learn about the latest developments in the emerging psychedelic medicine space